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Development of a Gene Therapy Virus with a
Glucocorticoid-Inducible MMP1 for the Treatment of
Steroid Glaucoma
Maria-Grazia Spiga and Teresa Borrás
PURPOSE. To design a glucocorticoid-inducible virus vector
overexpressing recombinant matrix metalloproteinase 1
(MMP1) and counteract extracellular matrix deposition in the
trabecular meshwork only when steroid is present.
METHODS. Endogenous MMP1 expression was measured in pri-
mary human trabecular meshwork cells (HTM) treated with
dexamethasone (DEX), triamcinolone acetate, and pred-
nisolone acetate by TaqMan PCR. Wild-type and mutant MMP1
cDNAs were cloned downstream of a glucocorticoid response
element (GRE) and PTAL promoter. Adenoviruses AdhGRE.
MMP1 and AdhGRE.mutMMP1 were generated by homologous
recombination. HTM cells and perfused human anterior seg-
ments were infected with the viruses, with and without DEX.
MMP1 mRNA and protein were analyzed by TaqMan PCR,
Western blot analysis, and ELISA. Activity of secreted MMP1
was evaluated by FRET and rat tail collagen type I assays.
Immunohistochemistry was performed by double-labeling with
anti-human MMP1 and collagen type I antibodies.
RESULTS. Endogenous MMP1 expression was greatly downregu-
lated by the steroids. DEX-treated cells and perfused organ
cultures infected with AdhGRE.MMP1 secreted high levels of
MMP1. Induction of MMP1 cycled on and off with the addition
or removal of DEX. Secreted wild-type MMP1 degraded colla-
gen type I after activation, whereas secreted mutMMP1 did not.
Immunohistochemistry showed faint staining of collagen type
I in areas of trabecular meshwork with high MMP1 transgene
expression.
CONCLUSIONS. The authors have developed a novel glucocorti-
coid-inducible adenovirus vector that overproduces MMP1
only in the presence of DEX. The availability of this vector sets
up the foundation for the development of gene therapy drugs
for the potential treatment of ocular hypertension in steroid-
responsive patients. (Invest Ophthalmol Vis Sci. 2010;51:
3029–3041) DOI:10.1167/iovs.09-4918
Glucocorticoids are potent immunosuppressants com-monly used for the treatment of many inflammatory dis-
orders, including ocular inflammation. Administration of glu-
cocorticoids can cause elevated intraocular pressure (IOP) and
can lead to open-angle glaucoma in steroid-responsive persons.
Topical ocular treatment with corticosteroids produces a dose-
dependent IOP increase in 30% to 40% of the general popula-
tion1,2 and in 90% of patients with primary open-angle glau-
coma (POAG).3 The ocular hypertension effect of the
glucocorticoids is significantly greater in older age groups and
is completely reversed after cessation of the treatment.1,4 Ste-
roid-responsive persons (steroid-responders) are more likely to
develop POAG than their nonresponder counterparts.5
Glaucoma is a multifactorial ocular disease characterized by
the death of retinal ganglion cells and degeneration of the optic
nerve. Glaucoma affects 70 million people worldwide and is
the second leading cause of irreversible blindness.6 It is well
established that the major risk factor for the development of
glaucoma is elevated IOP7 and that this elevated IOP is caused
by increased resistance to the aqueous humor outflow exerted
by the trabecular meshwork tissue.8 Potential mechanisms of
steroid-induced glaucoma have been extensively studied.9,10
Glucocorticoid exposure affects the expression of numerous
genes in the trabecular meshwork cells,11,12 and these changes
translate to characteristic morphologic and biochemical
changes of the outflow tissue.13 Glucocorticoids induce the
formation of cross-linked actin networks in trabecular mesh-
work cells and tissues.14 In vitro, dexamethasone (DEX) de-
creases trabecular meshwork phagocytosis,15 increases extra-
cellular matrix (ECM) deposition,16 induces the glaucoma-
linked gene myocilin,17 and decreases the expression and
activity of matrix metalloproteinases (MMPs). Together these
changes lead to impairment of the aqueous humor drainage
and contribute to the increased outflow resistance observed in
steroid-responder subjects.1
Glucocorticoid response occurs by the binding of the ste-
roid hormone to the intracellular glucocorticoid receptor alpha
(GR). The ligand-receptor complex dimerizes, translocates to
the nucleus, and binds to a DNA cis-acting glucocorticoid
response element (GRE) to modulate the expression of target
genes.18 A recent study on glucocorticoid responsiveness of
primary and transformed trabecular meshwork cells has shown
that treatment with DEX activates a GRE element inserted into
a transfected plasmid vector and is able to drive expression of
the GRE-driven reporter gene.19 These results indicate that the
transfected GRE regulatory element is active in the trabecular
meshwork and may induce the expression of other eukaryotic
genes.
The modulation of outflow resistance by medications with
longer durations of action than those of conventional drugs
remains the goal of glaucoma treatment. In the search for an
alternative treatment of glaucoma, our laboratory first devel-
oped the delivery and overexpression of transgenes to the
trabecular meshwork by the use of viral vectors.20,21 Our
studies have since been extensively reproduced by other lab-
oratories.22–24
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Recently, we have demonstrated that after a single intra-
cameral injection, some viral vectors can overexpress the de-
livered transgene in the trabecular meshwork of primates for
more than 2 years.25 However, continuous unregulated over-
expression of transgene products may result in an unwanted
physiological or toxic effect. A successful overexpressing, in-
sult-induced glaucoma gene drug would be one that could
increase the levels of its therapeutic product when the agent
triggering the disease is present and would stop its mode of
action when it is no longer needed. Therefore, in this study, we
hypothesized that the GRE regulatory element could be used to
drive the expression of a gene that, in turn, could counteract
the detrimental effects of glucocorticoids in the trabecular
meshwork. Because of the inducible nature of the GRE ele-
ment, the selected gene would then be expressed only when
the trabecular meshwork tissue was exposed to the glucocor-
ticoid.
Because of the relevance of the ECM in the regulation of
outflow facility26 and because of the well-established fact that
the administration of glucocorticoids leads to increased ECM
deposition,16 we chose to test our hypothesis by focusing on
MMPs. These enzymes comprise a family of zinc-containing
proteases that are secreted as inactive proenzymes and are
frequently regulated at the level of transcription. MMPs play a
key role in the turnover and maintenance of the trabecular
meshwork’s ECM and have been shown to be involved in
outflow facility.26,27 For this study, we selected MMP1. The
member MMP1 is an interstitial collagenase that breaks down
ECM collagens types I, II, and III. Collagen type I is an integral
component of the trabecular meshwork extracellular scaffold,
and it forms part of the central core of the trabecular mesh-
work beams. In the organ-cultured trabecular meshwork, col-
lagen type I protein is upregulated by DEX,28 whereas C-
propeptides of collagen type I are downregulated in a rat
steroid-induced ocular hypertension.29 MMP1 is a well-known
factor associated with tumor invasion and angiogenesis and has
been the subject of outflow facility studies.27,30 In the trabec-
ular meshwork in vitro, MMP1 expression is downregulated by
DEX11 and by overexpression of a nonsecreted myocilin mu-
tant.31 MMP1 is also downregulated by transforming-growth
factor  (TGF), a growth factor that induces fibrosis and
upregulates collagen type I,32 and delivery of MMP1 by infec-
tion with Ad5MMP1 attenuated liver fibrosis in the living rat.33
MMP1 is upregulated by wild-type myocilin,31 which is appar-
ently inconsistent with the fact that DEX also upregulates
myocilin. Experiments addressing this lack of correlation are
ongoing in our laboratory and are under the scope of a differ-
ent study. MMP1 is also upregulated by latanoprost.34 Interest-
ingly, transgenic mice containing a targeted mutation in the
gene for 1 subunit of collagen type I experienced elevated
IOP. This mutation codes for five amino acid substitutions
adjacent to the MMP1 cleavage site and blocks MMP1 activity,
which results in collagen type I accumulation and ocular hy-
pertension.35
With the intent of developing a gene therapy vector for the
treatment of steroid-induced glaucoma, we designed a recom-
binant adenoviral vector containing the full coding human
MMP1 cDNA under control of a GRE element and a basal
promoter. Delivery of this vector (AdhGRE.MMP1) to primary
human trabecular meshwork cells (HTM) and perfused post-
mortem human eye organ cultures secreted active MMP1 with
the ability to degrade collagen type I. In a second, coupled
study, delivery of the vector was able to reduce the steroid-
induced ocular hypertension in a large animal model.36 The
availability of this vector provides proof of concept and the
basis for development of gene therapy drugs for the treatment
of steroid-induced elevated IOP.
MATERIALS AND METHODS
Primary Culture of Human Outflow Facility Cells
To generate primary HTM cells, the trabecular meshwork tissue was
dissected from residual cornea rims after surgical corneal transplanta-
tion at the University of North Carolina Eye Clinic. Trabecular mesh-
works were isolated from surrounding tissue, cut into small pieces, and
treated with 1 mg/mL collagenase type IV (Worthington, Lakewood,
NJ), as described.37 Cells were maintained at 37°C, 7% CO2, in MEM
Richter’s modification medium (HyClone; Thermo Fisher Scientific,
Waltham, MA) supplemented with 20% FBS and 50 g/mL gentamicin
(Gibco Invitrogen, Carlsbad, CA). At confluence, cells were passed and
maintained in the same medium but with 10% FBS (complete medium).
All cells were used at passages 4 to 6. These outflow pathway cultures
include cells from the three distinct regions of the trabecular mesh-
work plus cells lining the Schlemm’s canal (SC). Because most of the
cells in these cultures come from the trabecular meshwork, they are
commonly referred to as trabecular meshwork cells. The cells used in
this study were from a 15-year-old Caucasian boy (HTM-109), a 2-year-
old Caucasian girl (HTM-95), a 19-year-old Caucasian man (HTM-106),
and a 54-year-old Caucasian woman (HTM-140).
Drug Treatments
Drug treatments on the HTM cells were conducted in complete media.
HTM cells were grown to preconfluence and were exposed to drugs as
follows: treatment with DEX (Sigma, St. Louis, MO) was conducted at
a final concentration of 0.1 M. DEX was reconstituted in absolute
ethanol at 0.1 mM and diluted 1000-fold into complete media every 48
to 72 hours for the duration of the experiment. Treatment with triam-
cinolone acetonide (Kenacort-A; Bristol-Myers Squibb, New York, NY)
was performed at a final concentration of 0.1 mg/mL. Kenacort-A 40
mg/mL suspension was mixed well and diluted into complete medium
400-fold at the time of use. The concentration of 0.1 mg/mL triamcin-
olone acetonide was chosen because intravitreal injections of 1 mg/mL
are widely used in the clinical setting and result in a lower concentra-
tion of the steroid in the aqueous humor. In addition, the concentra-
tion of 0.1 mg/mL has been successfully studied in trabecular mesh-
work cells.38 Treatment with prednisolone was conducted at a final
concentration of 200 M (80 g/mL). Prednisolone 21-acetate (Sigma)
was reconstituted in ethanol at 200 mM (80 mg/mL) as a suspension
and was mixed well before dilution of 1000-fold into the culture
medium. The drugs were exposed to the cells for the period described
in Results. Untreated control dishes received the same volume of
absolute ethanol (drug vehicle) under identical conditions.
RNA Extraction, Reverse Transcription,
and cDNA Quantification
HTM cells were scraped from tissue culture dishes with guanidine
thiocyanate buffer (RLT; Qiagen, Valencia, CA). Total RNA was ex-
tracted by loading the solution onto a column (QIA Shredder; Qiagen)
and was continued by the use of a kit with on-column RNase-free
DNase digestion (RNeasy Mini kit; Qiagen) in accordance with the
manufacturer’s recommendations. Purified RNA was eluted in 30 L
RNase-free water and concentration measured with a spectrophotom-
eter (NanoDrop ND-100; Thermo Fisher Scientific, Pittsburgh, PA). For
the tissue, human trabecular meshworks were excised from 1-week
RNA stabilization reagent (RNAlater; Ambion Applied Biosystems, Aus-
tin, TX) immersed anterior segments. Half the isolated trabecular mesh-
work tissue was homogenized on 350 L RLT, and RNA extraction
continued as described for the cells. Recoveries were between 1.4 to
2 g RNA per human trabecular meshwork.
Reverse transcription (RT) reactions were conducted with 1 g
(HTM cells) or 400 ng (tissue) RNA in a 20-L total volume of propri-
etary RT buffer with RNase inhibitor (High Capacity cDNA kit; Applied
Biosystems [ABI], Foster City, CA) in accordance with the manufactur-
er’s recommendations (25°C 10 minutes, 37°C 2 hours, and 85°C 5
seconds). Fluorescence-labeled TaqMan probe/primer sets for human
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MMP1 and 18S RNA were purchased from the ABI TaqMan gene
expression collection (http://www.allgenes.com). The human MMP1
probe corresponded to sequences from exons 6 and 7 (Hs00233958_m1),
and the 18S RNA probe corresponded to sequences surrounding po-
sition nucleotide 609 (Hs99999901_s1). Reactions were performed in
20-L aliquots (TaqMan Universal PCR Master mix No AmpErase UNG;
ABI), run on a PCR system (7500 Real-Time; ABI), and analyzed with
ABI software (7500 System SDS). Relative quantity (RQ) values be-
tween treated and untreated samples were calculated by the formula
2-CT, where CT is the cycle at threshold, CT is CT of the assayed
gene minus CT of the endogenous control (18S), and CT is the CT
of the normalized assayed gene in the treated sample minus the CT of
the same gene in the untreated sample (calibrator). Because of the high
abundance of the 18S rRNA used as the endogenous control and to get
a linear amplification, RT reactions from treated and untreated samples
were diluted 104 times before hybridization to the 18S TaqMan probe.
Protein Extraction, Western Blot Analysis, and
Protein Quantification
Serum-containing culture medium from treated and untreated HTM
cells was collected, cleared of cellular debris by centrifugation at 1500
rpm for 10 minutes, and concentrated 40 (10-kDa cutoff; Amicon
Ultra-4 Centrifugal Filter Device Ultracel; Millipore, Billerica, MA) at
3500 rpm, 4°C. After the removal of medium, HTM cells were washed
with cold phosphate-buffered saline (PBS) and harvested in 150 L
cold RIPA buffer (0.15 M NaCl, 0.02 M Tris-HCl, pH 8, 1% NP40, 1%
sodium deoxycholate, 0.1% SDS) supplemented with 1 protease
inhibitor cocktail (Roche Applied Biosciences, Indianapolis, IN). Cells
were disrupted with a sonicator (Microson Ultrasonic XL 2000; Miso-
nix, Farmingdale, NY) equipped with a 2.4-mm microprobe (Misonix)
at setting 3 for five pulses. The sonicate was then centrifuged at
14,000g for 20 minutes at 4°C, and supernatants (soluble fraction)
were collected and stored at 80°C until use. Serum-free effluents
from perfused organ cultures were concentrated 40 in the same
manner as media from the cultured cells.
Equivalent volumes from treated and untreated protein extracts,
concentrated media, or effluents were mixed 1:2 (vol/vol) with loading
Laemmli buffer (Bio-Rad, Hercules, CA) containing 5% -mercaptoetha-
nol and boiled for 5 minutes. Protein samples were separated on a 4%
to 15% SDS-PAGE precast gel (Bio-Rad) and electrotransferred to a
polyvinylidene difluoride membrane (Bio-Rad). After blocking with 5%
nonfat dry milk in 0.01 M Tris, pH 8.0, 0.1% Tween for 1 to 2 hours at
room temperature, membranes were incubated overnight at 4°C with
rabbit anti-human MMP1 (1:1000, AB8105; Millipore) or goat anti-
human collagen type I (1:200, AB758; Millipore) primary antibodies.
Membranes were then washed and incubated with anti-rabbit or anti-
goat IgG secondary antibodies conjugated to horseradish peroxidase
(HRP) (1:5000; Pierce Thermo Fisher Scientific, Rockford, IL) for 1
hour at room temperature. Immunoreactive bands were visualized by
chemiluminescence (ECL Plus; GE Healthcare, Piscataway, NJ) and
exposed to X-ray film (BioMax MR Film; Kodak, Rochester, NY). To
reprobe membranes with other primary antibodies, membranes were
stripped in 0.01 M Tris, 0.1% Tween, pH 2.0, for 15 minutes, washed,
and neutralized in the same buffer at pH 8.0. For controls, membranes
were incubated with mouse monoclonal anti-human -actin for 1 hour
at room temperature (1:5000, A5441; Sigma) or rabbit anti-human
myocilin (1:50, sc-21243; Santa Cruz Biotechnology, Santa Cruz, CA),
washed, and incubated with HRP-conjugated anti-mouse or anti-rabbit
IgG, respectively (1:5000; Pierce Thermo Fisher Scientific) for 1 hour
at room temperature.
Levels of secreted MMP1 in concentrated HTM-cultured medium
and effluents were determined by ELISA using a human MMP1 ELISA kit
(RayBiotech, Norcross, GA) in accordance with the manufacturer’s
recommendations. At the end of the incubation, immunoplates were
read at 450 nm in a microplate reader (FLUOstar Optima; BMG
Labtech, Cary, NC).
Adenovirus Construction and Titration
The details of adenovirus constructions are provided as Supplementary
Material, available at http://www.iovs.org/cgi/content/full/51/6/3029/
DC1. Physical particles were titered as virus genomes (vg)/milliliter by
real-time PCR using the MMP1 fluorescent TaqMan primers/probe
described (Hs00233958_mL; ABI). For this, viral DNA was extracted
from 5 L purified virus (DNeasy tissue kit; Qiagen), and amplification
reactions were set in triplicate. A standard curve was generated by
amplifying known copy numbers of MMP1 plasmid pMG19 (see Sup-
plementary Material) and plotting them against their threshold cycle
(CT) values. The number of virus genomes was then determined com-
paring the CT values of the viral DNA to the standard curve. Viral lots
used in this study had concentrations of 3.1  1011 (wild-type) and
4.0  1011 (mutant) virus genomes per milliliter, respectively.
Viral infectivity (infectious units [IFU]/mL) was measured with a
rapid titer kit (AdenoX; Clontech, Mountain View, CA) containing an
antibody specific to the adenovirus hexon capsid protein produced
only in infected cells. QBI-HEK293A cells were seeded in 12-well plates
to 90% confluence and were infected with serial dilutions (104–106)
of the adenovirus stock in duplicate wells. At 48 hours, cells were fixed
with ice-cold 100% methanol for 10 minutes at 20°C, washed with
PBS/1% BSA, and incubated with a mouse anti-hexon antibody (1:2000)
for 1 hour. Positive brown color spots were detected by incubation
with HRP-conjugated rat anti-mouse (1:1000, 1 hour at 37°C), washing,
and developing with 3,3-diaminobenzidine substrate. Brown spots
were counted with a 20 objective in an inverted microscope (IX71;
Olympus, Tokyo, Japan) equipped with a digital camera (DP70; Olym-
pus). Each brown-stained cell corresponds to one infectious viral
particle (IFU); wells from dilutions with approximately 50 spots per
field were chosen for counting. Quantification of the IFUs per milliliter
was made by averaging the number of spots in three to four fields per
well and applying the following formula: brown spots/field  fields/
well divided by virus volume used/well (mL)  virus dilution factor.
Under our conditions, there were 400 fields/well on a 12-well plate. A
correction factor for the area of the captured image (1.84) was
obtained by the use of a calibrated slide and introduced in the formula
to obtain the final titer. Viral lots used in this study had 1.8  1011
(wild-type) and 2.1  1011 (mutant) IFU/mL, respectively.
Delivery of Recombinant Adenoviruses to
HTM Cells
HTM primary cells at passage 4 seeded on six-well dishes were grown
to 90% confluence, washed twice with PBS, and exposed to the
recombinant adenoviruses AdhGRE.MMP1 and AdhGRE.mutMMP1 in 1
mL serum-free medium. After exposure to the virus for 90 minutes,
complete media containing 0.1 M DEX was added, and incubation
continued for 3 to 5 days. Fresh DEX medium was replaced at 48- to
72-hour intervals, as indicated. Viral concentrations were at a multi-
plicity of infection (MOI) ranging from 2.3 to 2.6  103 IFU/cell.
Measurement of MMP1 Activity by Collagen
Degradation Assays
To determine the collagenase activity of the human recombinant
MMP1 secreted in the media, we performed two assays: the fluores-
cence resonance energy transfer (FRET) assay, which incorporates the
FRET pair labeling technology in an MMP peptide substrate, and the
digestion of native rat tail collagen type I measured by gel electro-
phoresis. Conditioned media from postinfected dishes treated with
steroids were cleared of cellular debris and concentrated 40, as
indicated. To activate pro-MMP1 from its latent state, samples were
incubated at 37°C for 3 hours in 1 mM p-aminophenylmercuric acetate
(APMA)39 in a total volume of 50 L. Commercially available purified
pro-MMP1 (AnaSpec, Fremont, CA) was used as a positive control.
For the FRET assay, 10 L concentrated activated serum-containing
media were incubated with the 5-FAM/QXL 520–labeled peptide for
40 minutes at 37°C in accordance with the manufacturer’s recommen-
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dations (SensoLyte 520 MMP -1 Assay Kit; AnaSpec). Enzyme activity
was determined by measuring the fluorescence released on proteolytic
cleavage of the fluorescent peptide in a microplate reader (FLUOstar
Optima) using 480/520-nm excitation/emission filters. To test the en-
zymatic activity against native collagen, 5 L activated serum-free
media were incubated with 10 g native rat tail collagen type I (BD
Biosciences, San Jose, CA) for 2 hours at 37°C in a total volume of 28
L.40 Half the reaction volume was analyzed in a 4% to 15% Tris-HCl
PAGE gel (Bio-Rad) at 100 V for 1.5 hours. Gels were subsequently
washed with water and stained (Biosafe Coomassie G-250; Bio-Rad) at
4°C overnight. Bands were visualized after a final wash and were
photographed with a digital camera (SD850 IS; Canon, Lake Success,
NY).
Perfused Human Anterior Segment
Organ Cultures
Three pairs of normal, nonglaucomatous human eyes from donors ages
72 to 74 were obtained from the National Disease Research Inter-
change (Philadelphia, PA) with the signed consent of the patients’
families. All procedures were conducted in accordance with the tenets
of the Declaration of Helsinki. Whole eye globes within 22 to 43 hours
of death were dissected at the equator, cleaned, and mounted on
custom-made perfusion chambers, as described previously.20,41 These
anterior segments were perfused at constant flow (3–6 L/min)
through one of chamber’s two cannulas with serum-free, high-glucose
DMEM (Gibco Invitrogen) containing antibiotics, using a Harvard mi-
croinfusion pump (Harvard Bioscience, South Natick, MA). HPLC
pumps (MX7900–000; Rheodyne, Rhonert Park, CA) equipped with a
20-L loop were intercalated between perfusion syringes and cham-
bers so that virus could be administered without injection through the
cornea. All pumps were controlled by a custom-made computer pro-
gram (Infusion Pump Control Program, University of North Carolina
Chemistry Department, Electronic Design Facility). Anterior segments
were maintained at 37°C, 5% CO2, and perfused for 24 hours to
establish a stable baseline (steady pressure recordings for at least 10
hours). Outflow facility (flow/pressure in L/min/mm Hg) was calcu-
lated from the average of three values obtained from pressure readings
recorded at 30-minute intervals. Baseline values were taken just before
the steroid treatment and sample delivery. The outflow facility at
baseline for the eyes used in this study was C  0.29  0.03 (n  6).
After obtaining a stable baseline, the perfusion syringes and eyes’
anterior chambers were exchanged with fresh media containing 0.1
M DEX. At the same time, HPLC loops were loaded with AdhGRE.
MMP1 (for OS) or virus vehicle (for OD), which were delivered into
the eyes by remote control loop injection from the computer. Fresh
DEX media were changed approximately every 36 hours, and effluents
were collected from the chamber reservoirs at different time points
and saved at 20°C for analysis of secreted proteins. At the end of the
experiment, anterior segments were cut in several wedges that were
immersed in either 4% paraformaldehyde or RNA stabilization reagent




Cells were cultured on glass coverslips precoated with poly-D-lysine,
fixed, and fluorescence double labeled for the MMP1 and collagen type
I proteins. Cells were washed, fixed with 4% paraformaldehyde for 10
minutes, permeabilized with 0.1% Triton X-100/PBS for 10 minutes,
washed, and blocked with 2% donkey serum/PBS for 30 minutes.
Coverslips were simultaneously incubated with rabbit anti-human
MMP1 antibody (1:500, AB8105; Millipore) and goat-anti collagen type
I (1:100, AB758; Millipore) for 1 hour at room temperature, followed
by an additional 1 hour with a mixture of donkey anti-rabbit Alexa
Fluor 555 and donkey anti-goat Alexa Fluor 488, respectively (1:400;
Molecular Probes Invitrogen). All antibody solutions were made in 2%
donkey serum, and three washes were performed between incubation
steps. All secondary antibodies were tested for cross-reactivity by
incubating coverslips in the absence of the primary antibodies. Cells
were counterstained with 4,6-diamidino-2-phenylindole (DAPI) for 3
minutes before the coverslips were mounted with a drop of water-
soluble, nonfluorescing compound (Fluoromount G; Southern Biotech-
nology Associates, Birmingham, AL).
Eyes from pairs 2 and 3 were fixed by immersion in 4% parafor-
maldehyde in PBS at room temperature overnight. Specimens were
then rinsed in distilled water for 10 minutes and transferred to 70%
ethanol for delivery to the University of North Carolina Histology Core
for paraffin embedding. Meridional 10-m sections from opposite
quadrants of each eye were mounted on microscope slides (Super-
frost/Premium; Thermo Fisher Scientific). For MMP1 and collagen type
I detection, sections were first incubated at 60°C for 1 hour, deparaf-
finized with xylene (2  7 minutes), rinsed with descending concen-
trations of ethanol (100% for 5 minutes, 95% for 4 minutes, 75% for 3
minutes), and rehydrated with distilled water for 2 minutes. Heat-
induced antigen retrieval was achieved by treating the sections with
unmasking solution (Vector Laboratories, Burlingame, CA) for 30 sec-
onds at 125°C in a decloaking chamber (Biocare Medical, Concord,
CA). Slides were then cooled off, washed with PBS, permeabilized with
0.1% Triton X-100/PBS for 10 minutes, washed again, and blocked with
2% donkey serum/PBS for 30 minutes. Tissue sections were incubated
with the same MMP1 (1:500; 2 hours at room temperature) and colla-
gen type I (1:200, overnight at 4°C) primary antibodies used for the
cells, followed by incubation with donkey anti-rabbit Alexa Fluor 555
and donkey anti-goat Alexa Fluor 488 secondary antibodies (1:200;
Molecular Probes Invitrogen) at room temperature for 1 hour. Sections
were mounted with coverslips and water-soluble, nonfluorescing com-
pound (Fluoromount G; Southern Biotechnology Associates) and
sealed with clear enamel. Fluorescence imaging was conducted with a
fluorescence microscope (IX71; Olympus), and images were captured
with a camera (DP70; Olympus) and accompanying software. Images
from corresponding viral- and vehicle-treated sections were taken at
the same exposure. Digital images were arranged with image analysis
software (Photoshop CS; Adobe, Mountain View, CA). Negative con-
trols were run in parallel but were incubated in blocking buffer in
place of the primary antibody.
RESULTS
Effect of Steroids on Endogenous
MMP1 Expression
Previous studies have shown that DEX treatment of cultured
HTM cells decreases the expression of several MMPs, including
MMP1, 2, 3, and 9.11,42,43 To specifically confirm and readdress
the effect of glucocorticoid treatment on MMP1 expression,
we treated primary HTM-109 cells with DEX, triamcinolone
acetonide, and prednisolone and measured levels of 18S nor-
malized MMP1 cDNA by real-time TaqMan PCR. Treatment
with 0.1 M DEX in a representative experiment reduced
MMP1 expression to relative quantification values of 0.03 
0.0002 at 3 days (n  3; P  7  107) and of 0.002  0.0002
at 6 days (n  3; P  1  106; Fig. 1A). Removal of DEX from
the cultured medium at 3 days prevented the MMP1 reduction
observed at day 6 (0.03  0.002; n  6; P  2  109; Fig. 1A).
Analysis of secreted proteins by Western blot conducted in a
different experiment showed that MMP1 protein was also re-
duced in the DEX-treated sample at 5 days while cross-reaction
of the stripped blot with myocilin (internal control) was in-
creased (Fig. 1B). These DEX findings were confirmed in four
additional mRNA and two additional protein experiments with
similar results. Treatment of the cells with 0.1 mg/mL triam-
cinolone acetonide and 80 g/mL prednisolone in a represen-
tative experiment reduced MMP1 cDNA levels to 0.42  0.1
(n  3; P  0.013) and 0.16  0.02 (n  3; P  0.002) at 12
and 24 hours, respectively (Fig. 1C). The experiment was
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repeated once in an HTM-140 cell line with similar findings.
These results indicate that treatment with glucocorticoids com-
monly used in a clinical setting specifically reduced the expres-
sion of MMP1 in primary HTM cells.
Design of a Glucocorticoid-Inducible Vector to
Counteract the DEX Effect on Trabecular
Meshwork ECM
Given a previous microarray report11 and our results regarding
the specific downregulation of MMP1, we hypothesized that
this enzyme could be a key mediator of increased ECM depo-
sition caused by glucocorticoids in the trabecular meshwork.16
We then reasoned that increasing the level of MMP1 expres-
sion only at the time of glucocorticoid treatment could coun-
teract its negative effects on the ECM and possibly lead to
lowering IOP. To achieve this regulated expression, we de-
signed a glucocorticoid-inducible vector in which human re-
combinant MMP1 cDNA expression would be under the con-
trol of the cis-acting GRE.
RNA was reverse transcribed, and the full-coding MMP1
sequence (1410 nucleotides) was amplified with restriction
site-ended primers containing a Kozak sequence, as indicated
in the Supplementary Material. The MMP1 cDNA was inserted
downstream of three tandem copies of the GRE consensus
sequence fused to a TATA-like promoter region from the HSV-
thymidine kinase gene available in the commercial vector
pGRE.Luc (Clontech). The GRE consensus element consists of
a nonperfect palindromic sequence (GGTACAnnnTGTTCT)
that is part of a GC regulatory response unit and can involve
more than one GRE, half-site GREs, and even negative GREs.44
To avoid spurious transcription from upstream sequences, the
vector contains a transcription blocker (TrBlk) upstream of the
GRE element. This 154-bp TrBlk contains a synthetic polyA site
and a transcription pause site from the 2 globin gene.45 The
entire MMP1 expression cassette (TrBlk.GRE.PTAL.MMP1.pA)
was then inserted into a shuttle vector to generate the recom-
binant adenovirus vector, as indicated in the Supplementary
Material (AdhGRE.MMP1; Figs. 2A, 2B).
A negative functional control vector containing a mutation
in the MMP1 active catalytic site was also generated (AdhGRE.
mutMMP1; Fig. 2C). This mutant MMP1 cDNA contains two
nucleotide changes at positions 653 and 1115 cDNA that ren-
der histidine-to-arginine and arginine-to-lysine amino acid
changes, respectively. The first of the two changes affects
His199, which is one of the three essential zinc-binding ligands
present in the active site. This change leads to improper fold-
FIGURE 1. Glucocorticoid effect on endogenous MMP1 expression in human trabecular meshwork cells.
Primary HTM cells were treated with the indicated glucocorticoids in serum-containing medium. Control
cells were treated with drug vehicle (untreated [UNT]). After treatment, cells were processed for RNA
extraction, RT reaction, and real-time TaqMan PCR using MMP1 and 18S TaqMan probes. Changes in gene
expression were measured in relative quantity units (RQ) to the vehicle-treated cells (n  number of
measurements in a representative experiment). (A) Confluent cells were exposed to 0.1 M DEX for up
to 6 days (n  3 each). In one well, DEX was removed at 3 days and harvested 3 days later (n  6). (B)
Media from DEX-treated cells were assayed in 4% to 15% SDS-PAGE gels and probed with anti-human
MMP1 antibody; after stripping, the membrane was reprobed with anti-human myocilin antibody as
internal control. (C) Subconfluent cells were treated with triamcinolone acetonide (TA; 0.1 mg/mL) for 12
hours (left) or prednisolone 21-acetate (PRED; 80 g/mL) for 24 hours (right; n  3 each). *P  0.013.
HTM cells treated with three different glucocorticoids; greatly downregulated expression of endogenous
MMP1.
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ing of the protein and destroys the catalytic activity of MMP1.46




To evaluate the expression levels of recombinant MMP1 in
response to DEX treatment, we infected 80% confluent HTM-
109 cells with either AdhGRE.MMP1 or AdhGRE.mutMMP1
(MOI 5000 and 6600 vg/cell, respectively) for 5 days in the
presence or absence of 0.1 M DEX. Results from a represen-
tative experiment showed that the normalized level of MMP1
mRNA in the wild-type–infected, DEX-treated samples was
79.2  9.8-fold of the infected untreated controls (n  3; P 
5  106). MMP1 expression of the mutant-infected, DEX-
treated cells was 83.2  10.1-fold of the infected untreated
controls (n  3; P  1  106). This high value of expression
by the mutant MMP1 virus is expected because the MMP1
mutations are not supposed to affect gene transcription (Fig.
3A). The experiment was repeated once with similar findings.
To determine the levels of recombinant MMP1 protein in
HTM cells infected with AdhGRE.MMP1, immunoblotting anal-
ysis was carried out for both conditioned media and cell ly-
sates. Our results showed that infected cells treated with DEX
produced high levels of recombinant MMP1 protein in the
cell-associated and secreted fractions compared with infected,
untreated cells (Fig. 3B). Additional quantification of secreted
MMP1 levels after AdhGRE.MMP1 infection was determined by
ELISA. At 5 days after infection, recombinant MMP1 levels in
DEX-treated HTM cells were 6491  169 ng/mL 9 (n  2)
compared with 282  32 ng/mL (n  2) in infected untreated
cells, respectively, which correspond to a 23-fold induction on
DEX treatment. Repeated experiments, also including infection
with the mutated virus, confirmed these findings. They further
revealed that the level of secreted protein in the AdhGRE.mut-
MMP1-infected cells was reduced 8.0  2.4 times (n  3),
suggesting that the mutated protein might be either secretion
impaired or subjected to easier degradation than the wild type.
Taken together, the results indicate that cells treated with
DEX can induce high expression of MMP1 in cells infected
with adenovirus vector at both the mRNA and the protein
levels.
Sequential ON and OFF Regulation of Delivered
MMP1 by Dexamethasone
Once a gene is delivered, one of the goals of using an inducible
vector is to be able to turn its expression off and back on again
when the corticosteroid stimuli is reapplied. To test the ability
of AdhGRE.MMP1 to express the gene under those conditions,
we infected HTM-109 cells with 5.1  103 vg/cell and treated
them with 0.1 M DEX. In two wells, DEX was removed at day
3 for 3 days, and added back in one of them for an additional
3 days (3d DEX, 3d noDEX, 3d DEX). Results of MMP1 cDNA
levels from a representative experiment are shown in Figure 4.
DEX induction for 3 days increased the expression of recom-
binant MMP1, as expected, to 11.7  1.4-fold (n  3; P  2 
105). Removal of DEX from the media reversed the induction
to 3.4  0.29-fold (n  3; P  0.0002), which was 11.7% of the
dish that received DEX continuously for the 6 days (29.1 
2.0-fold; n  3; P  5  106). Reinduction with DEX for
another 3 days restored the levels of MMP1 close to the original
level (14.8  1.2-fold; n  3; P  0.0003). Two more exper-
iments confirmed the findings. These results indicate that dur-
ing periods of DEX absence, the vector does not induce over-
expression of the recombinant gene. This is important because
overexpression under normal physiological conditions could
be damaging for the cells and tissues.
Collagenase Activity of the HTM
Adenovirus-Infected Culture Medium
To determine the enzymatic activity of the recombinant MMP1
protein and its ability to degrade collagen, we measured colla-
FIGURE 2. Schematic representation
of the construction of glucocorti-
coid-inducible virus vectors express-
ing MMP1. (A) A glucocorticoid-in-
ducible shuttle vector containing the
full-coding MMP1 (pMG17) was gen-
erated by first inserting the MMP1-
amplified RT from AdhTIG3-infected
cells downstream of the TrBlk.GRE.
pTAL element of plasmid vector
pGRE-Luc (pMG12); this was fol-
lowed by subcloning the full
GRE.MMP1 cassette into pShuttle
vector using NotI/SalI enzymes. (B)
AdhGRE.MMP1 recombinant virus
DNA was generated from a plasmid
obtained by overlapping recombina-
tion of electroporated linear pMG17
DNA and the adenovirus backbone
vector inside the BJ5183-Ad1 cells. (C)
AdhGRE.mutMMP1 recombinant vi-
rus DNA was generated in a similar
matter, except that the full-coding
MMP1 cDNA contained two single-
point mutations; one of the muta-
tions is at the catalytic site. Ad-re-
combinant plasmid DNAs from wild-
type and mutant MMP1 were
subsequently digested with PacI and
transfected into QBI-HEK293A cells
for the generation of the viral parti-
cles.
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gen breakdown of the steroid-treated infected cells’ media on
two independent assays. On the first assay, we measured the
ability of the DEX-induced infected media to degrade native rat
collagen type I by gel electrophoresis. HTM-109 cells at 80% to
90% confluence in six-well dishes were infected with Adh-
GRE.MMP1 and AdhGRE.mutMMP1 (MOI 5000 and 6600 vg/
cell, respectively) and were treated with DEX for 5 to 7 days
(n  3). Serum was removed for the last 3 days of the exper-
iment, and media were collected for Western blot analysis with
MMP1 antibody, as indicated in Materials and Methods. Incu-
bation of the concentrated media with APMA for 3 hours
resulted in the switch of the pro-MMP1 band (51 kDa) to the
lower, active form of the human MMP1 (41 kDa; Fig. 5A).
Incubation of 25 ng purified pro-MMP1 (AnaSpec) was used in
parallel as a positive control (Fig. 5A).
Activated media from the AdhGRE.MMP1-infected dishes
treated with DEX digested native collagen type I into smaller
fragments (Fig. 5B, lane 5). The digested products are the 3⁄4
and the 1⁄4 fragments of the 1 and 2 chains, respectively, and
correspond to those previously defined as cleaved by MMP1.40
In contrast, medium from cells infected with AdhGRE.mutMMP1
and overexpressing MMP1 did not exhibit MMP1 enzymatic
activity and was unable to cleave collagen (Fig. 5B, lane 9),
consistent with the expression of a recombinant mutant MMP1
protein lacking an active catalytic site. In the absence of DEX,
the sensitivity of the gel assay was insufficient to detect colla-
gen digestion by the secreted wild type (Fig. 5B, lane 3), which
was nonetheless observed by the high sensitivity fluorescence
assay (Figs. 5C, 5D).
On this second assay, we measured the potential of the
conditioned media to degrade a fluorescence-labeled MMP1
substrate FRET peptide (AnaSpec). HTM-109 cells at 80% to
90% confluence in six-well dishes were infected with Adh-
FIGURE 3. DEX-induced overproduc-
tion of recombinant MMP1 in HTM
cells. Subconfluent primary HTM cells
were infected with adenovirus vec-
tors AdhGRE.MMP1 (wild-type) and
AdhGRE.mutMMP1 (mutant). Cells
were treated with 0.1 M DEX at
infection and every 2 to 3 days there-
after. Control cells were treated with
vehicle (untreated [UNT]). Five days
after infection and treatment, cells
were harvested for RNA or protein and
were processed for TaqMan assays or
Western blot analysis (n  number of
measurements in a representative ex-
periment). (A) Fold changes of wild-
type and mutant MMP1 cDNA ex-
pression in infected/DEX-treated cells
over infected/untreated controls nor-
malized to 18S (n  3 each). (B)
Western blot analysis of cell-associ-
ated and secreted MMP1 in infected/
DEX-treated and infected/untreated
samples probed with anti-human
MMP1 (n  3 each). *P  5  106.
Expression of MMP1 in infected cells
(mRNA and protein) is highly up-
regulated in the presence of DEX but
is barely expressed in the absence of
glucocorticoid treatment. High levels
of mutant mRNA and protein were
expected because the mutation only
blocks MMP1 activity.
FIGURE 4. Reversal of DEX induction of MMP1 in wild-type virus-
infected cells on removal of the glucocorticoid. Subconfluent primary
HTM cells in six-well plates were infected with AdhGRE-MMP1 and
treated with 0.1 M DEX at t  0. One well was left untreated (UNT).
DEX was removed from two infected wells at t  3 days and added
again to one of the two at 6 days. Cells were harvested at the indicated
times and were processed for RNA, RT, and TaqMan real-time with
MMP1 and 18S probes (n  number of measurements in a represen-
tative experiment). MMP1 was upregulated at 3 and 6 days after DEX
treatment. This transgene MMP1 upregulation disappeared on the
removal of DEX and returned on the reapplication of the corticosteroid
(n  3 each). *P  0.0002. Cells continuously carrying the MMP1 gene
transfer vector can turn on and off the transgene in the presence or
absence of the glucocorticoid.
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GRE.MMP1 and AdhGRE.mutMMP1 (MOI 5000 and 6600 vg/
cell respectively) and were treated with DEX or left untreated
for 5 days (n  3). Media were cleared of cellular debris,
concentrated 40, and treated with APMA, as indicated in
Materials and Methods. Equivalent aliquots of treated and con-
trol dishes were incubated with the labeled collagen FRET
peptide, and the released fluorescence of the cleaved peptide
was read in the fluorophotometer (Fig. 5C). The average of
three independent experiments is shown in Figure 5D. Relative
fluorescence units of the media of uninfected dishes were
2719  292 and 1607  63 for the untreated and DEX-treated
cells, respectively. Media from wild-type (AdhGRE.MMP1)-in-
fected dishes showed 5712  550 in the untreated and
59,013  148 in DEX-treated cells. In contrast, media from
cells infected with AdhGRE.mutMMP1 gave 4384  512 and
1945  101 in the untreated and DEX-treated samples, respec-
tively. The statistical comparison between the DEX-treated
wild-type and mutant was highly significant (P  1  109; Fig.
5D). Validation of equivalent cell numbers in treated and un-
treated dishes was performed in one experiment by measuring
intracellular lactate dehydrogenase (LDH) levels (0.96 vs. 1.27
OD492/mL in uninfected dishes, 1.29 vs. 1.24 OD492/mL, and
1.30 vs. 1.23 OD492/mL in wild-type and mutant virus infected,
respectively) using an LDH assay kit (Promega, Madison, WI).
Altogether these results indicate that only the recombinant
virus with the GRE element driving the wild-type MMP1 se-
cretes the active collagenase when exposed to the glucocorti-
coid. In addition, the data confirm that, in addition to MMP1
mRNA and protein levels (Figs. 1A, 1B), DEX also downregu-
lated the activity of MMP-1 (Fig. 5D). Altogether these data
indicate that the recombinant MMP1 produced by the AdhGRE.
MMP1 virus is able to cleave collagen type I in vitro.
Local Effect of MMP1 Overexpression on Primary
HTM Cells
The effect of overexpressing MMP1 in situ was assessed by
immunocytochemistry. Primary HTM-106 cells grown in cov-
erslips were treated with 0.1 M DEX and infected with 2.5 
103 vg/cell AdhGRE.MMP1. Localization of collagen type I and
MMP1 were detected at 48 hours after infection by double
labeling with the corresponding primary and secondary anti-
bodies described in Materials and Methods. Figure 6 demon-
strates that individual cells overexpressing MMP1 (infected by
the virus) exhibited lower levels of collagen type 1 than did
cells that were not infected. Conversely, cells with lower
MMP1 expression exhibited higher staining intensity for colla-
gen type I. These results indicate that the recombinant MMP1
has a local effect on the collagen of HTM cells. In addition,
some of the recombinant MMP1 appeared associated with the
cell nuclei. Although this localization was originally unex-
pected, it has been reported that the transfection of recombi-
nant MMP1 did associate with nuclei and mitochondria in
human Müller cells.47
Effect of MMP1 Overexpression on Perfused
Human Anterior Segments
To best mimic an in vivo situation, we next assessed the
delivery and DEX induction of the AdhGRE.MMP1 vector to the
intact human TM in the perfused organ culture system. We
FIGURE 5. Enzymatic activity of se-
creted recombinant MMP1 in HTM
cells. Subconfluent primary HTM
cells were infected with wild-type or
mutant adenovirus vectors (AdhGRE.
MMP1 and AdhGRE.mutMMP1) and
were treated with 0.1 M DEX at t 
0. Media were concentrated 40.
(A) Ten microliters of media, col-
lected 5 days after wild-type infec-
tion, were incubated with 1 mM
APMA for 3 hours to cleave pro-
MMP1 enzyme-inhibitor complex (51
kDa) and release the active MMP1
(41 kDa). Commercial purified pro-
MMP1 protein was used as positive
control. Western blot analysis was
probed with an anti-MMP1 antibody
that detected both the latent and the
active form. (B) Five microliters of
serum-free media, collected 7 days
after infection, untreated and treated
with DEX, were activated and incu-
bated with rat tail native collagen
type I (10 g) for 2 hours. Samples
were run on a 4% to 15% PAGE gel
and were stained with Coomassie
blue. (C) Schematic representation
of the FRET assay: a MMP substrate
peptide labeled with a 5-FAM (fluoro-
phore) and QXL52 (quencher) re-
leases the fluorophore after cleavage
of the peptide by MMP1. Fluores-
cence is read using 490/520 nm
EX/EM filters. (D) Ten microliters of
serum-containing media, collected 5
days after infection, untreated or
treated with DEX, were activated and
incubated with the FRET peptide for 40 minutes at 37°C (n  3 independent experiments). MMP1 activity was expressed in relative fluorescence
units of the sample with higher activity. Although the MMP1 produced by the mutant was inactive, the MMP1 produced by the wild-type adenovirus
was activated by APMA, degraded native collagen type I, and cleaved the FRET peptide with high efficiency. *P  1  109.
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examined the expression levels of MMP1 and measured the
ability of the secreted MMP1 to degrade collagen by the FRET
assay and immunohistochemistry. Three nonglaucomatous eye
pairs from postmortem donors were perfused at constant flow
and treated with 0.1 M DEX, as indicated in Materials and
Methods. The HPLC valve connected to one eye was loaded
with 6.2  109 vg AdhGRE.MMP1 at the time of DEX treatment
(t  0; eye pair 1) or twice (t  0 and t  24 h; eye pairs 2 and
3). The HPLC connected to the contralateral eye was loaded
with virus vehicle at the same times.
Examination of the delivered MMP1 cDNA in the dissected
tissue showed that the mRNA level in the viral injected eye was
increased 3977  220-fold over that of the vehicle-injected one
(eye 1, n  3; P  1  108; Fig. 7A). Equivalent aliquots from
40 concentrated effluents from the same eye pair analyzed by
Western blot analysis showed similar MMP1 band intensities at
preinjection time, whereas the intensity increased consider-
ably in the eye injected with AdhGRE.MMP1 at 3 and 5 postin-
jection days (Fig. 7B). Both pro-MMP1 and MMP1 were ob-
served after perfusion with DEX. Quantification of MMP1 levels
in these effluents was determined by ELISA at dilutions of
1:1000, each in duplicate. At preinjection, MMP1 levels were
similar in the effluent of both eyes (310 and 317 ng/mL,
respectively). At 3 days postinjection, MMP1 levels in the
effluent of the AdhGRE.MMP1-injected eye increased 2.4-fold
over those in the vehicle-injected eye (409 vs. 168 ng/mL). At
5 days, MMP1 levels in the AdhGRE.MMP1-injected eye
reached 4.9-fold over those in the vehicle-injected eye (842 vs.
143 ng/mL).
Activity of the MMP1 enzyme by two different assays is
shown in Figure 8. The FRET assay was performed on eye pairs
2 and 3. The ratio of relative fluorescence units in viral- and
vehicle-injected eyes (OS/OD) effluents from pair 2 was 1.3-
fold at preinjection time and reached 4.7- and 8.7-fold at 2 and
3 days postinjection, respectively (Fig. 8A). In effluents from
eye pair 3, the ratio was 1.3-fold at preinjection time and
reached 2.8- and 20.0-fold at 1 and 2 days postinjection, re-
spectively. Concentrated effluents from eye pair 1 were run on
PAGE gels, electroblotted, and sequentially probed with MMP1
and collagen type I antibodies, as described in Materials and
Methods. Results in Figure 8B showed that the intensity of
MMP1 protein bands was higher in the effluent of the viral-
injected eye than in that of the vehicle-injected control. Con-
versely, collagen type I bands appeared to be more intense in
the vehicle-injected than in the virus-injected eye, concomitant
with the presence of a higher activity of the collagenase.
Together, these results indicate that the vector successfully
enters the cells of the trabecular meshwork tissue, is overex-
pressed in the presence of DEX, and secretes active MMP1 into
the effluent media.
FIGURE 6. Local effect of overexpressing MMP1 in HTM cells. Forty percent confluent primary HTM cells
in coverslips were infected with 2.5  103 vg/cell AdhGRE.MMP1 in the presence of 0.1 M DEX. After
48 hours, cells were fixed and incubated simultaneously with human anti-MMP1 and anti-collagen type I
antibodies, followed by fluorescence-tagged Alexa Fluor 555 (for MMP1, red) and Alexa Fluor 488 (for
collagen type I, green) antibodies. Cells were counterstained with DAPI (blue). Shown is a single frame
captured under Texas Red, FITC, and DAPI filters. A representative infected cell (thick arrows) showed
increased MMP1 and decreased collagen type I. A representative uninfected cell (thin arrows) showed
higher levels of collagen type I in the presence of lower levels of MMP1.
FIGURE 7. Characterization of adenovirus-delivered MMP1 in perfused
human anterior segments. Eye pairs from nonglaucomatous donors
were perfused to stable baseline with DMEM and followed by media
exchange containing 0.1 M DEX in both eyes. At this time, eyes were
injected through an HPLC loop, and perfusion continued with DMEM/
DEX media. One eye received virus vehicle (OD), whereas the con-
tralateral eye received 6.2  109 vg AdhGRE.MMP1 (OS). The trabec-
ular meshwork tissue was dissected at the end of the experiment and
harvested for RNA and TaqMan assays. Effluents were collected at 3
and 5 days after infection and were processed for the analysis of
secreted MMP1. (A) Fold changes of MMP1 transgene (OS) over vehi-
cle-injected (OD) expression using MMP1 and 18S TaqMan probes (eye
pair 1, 5 days after injection; n  3; *P  1  108). (B) Equivalent
aliquots of concentrated effluents from the same eye pair analyzed by
Western blot analysis with a human anti-MMP1 antibody. Delivery of
the MMP1 transgene to the OS eye by the adenovirus vector is highly
efficient. Perfusion with DEX results in the secretion of pro-MMP1 and
MMP1 forms (latent and active).
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At 60 hours after injection, the average of the percentage
changes of outflow facility from baseline of the three eye pairs
treated with AdhGRE.MMP1 increased 17.9%  5.9% L/
min/mm Hg over that of the vehicle-treated eyes. These pre-
liminary results, showing an increase in outflow facility with
overexpression of MMP1, were the first indication of this
vector’s potential for a physiological effect in lowering IOP
(see Ref. 36).
The increase in MMP1 and the decrease in collagen could
also be observed by immunohistochemistry of the trabecular
meshwork tissue by MMP1/collagen type I double labeling of
sections from different quadrants in eye pairs 2 and 3 (Fig. 9).
In regions of the trabecular meshwork in which MMP1 is
intensively stained, collagen type I staining is faint, especially
on the inner wall of the SC and in the juxtacanalicular region
(Fig. 9). These images also show that the architecture and cell
number of the trabecular meshwork tissue were not detrimen-
tally affected by infection with the virus and subsequent over-
expression of MMP1. All regions of the outflow tissue appeared
healthy and conserved the canonical layered trabecular mesh-
work structure and well-formed SC.
DISCUSSION
One of the significant side effects of corticosteroid therapy is
the induction of ocular hypertension that, if untreated, would
result in the development of steroid-induced glaucoma.10,48 To
address this unwanted clinical effect at the molecular level, in
the present study we report the development of a gene therapy
vector for the potential treatment of steroid-induced glaucoma.
Our results first showed that human primary trabecular
meshwork cells treated with corticosteroids greatly downregu-
lated MMP1, a metalloproteinase shown to be involved in the
ECM turnover of the trabecular meshwork. MMP1 is required
for the maintenance of outflow facility and is upregulated by
conditions that lower resistance of the trabecular meshwork
and IOP.9 The three steroids tested here, DEX, triamcinolone
acetonide (Kenacort-A; Bristol-Myers Squibb), and pred-
nisolone acetate, are widely used in the clinical setting. In
particular, the use of intravitreal triamcinolone acetonide
(Kenacort-A; Bristol-Myers Squibb) has become very popular
for the treatment of macular edema and choroidal neovascu-
larization, and, as a result of this heavy use, more patients are
experiencing elevated IOP.49 At the transcriptional level, our
FIGURE 8. Functional activity of transgene MMP1 delivered to per-
fused human anterior segments. Eye pairs from nonglaucomatous do-
nors were perfused to stable baseline with DMEM and followed by
media exchange containing 0.1 M DEX in both eyes (t  0). Eyes
were injected through an HPLC loop, and perfusion continued in
DMEM/DEX media. One eye (OD) received virus vehicle while the
contralateral eye (OS) received 6.2  109 vg/dose AdhGRE.MMP1.
Effluents were collected at preinjection and postinjection times, con-
centrated 40, activated with APMA, and assayed for MMP1 activity.
(A) Ten-microliter effluents from OD (vehicle) and OS (wild-type
MMP1 adenovirus) were incubated with the FRET peptide for 40
minutes at 37°C. MMP1 activity was measured by quantifying the
released fluorescence from the substrate peptide, and it was expressed
in ratio of relative fluorescence units of the viral- treated over vehicle
(OS/OD; eye pair 2, injected twice at t  0 and t  24 hours). (B)
Equivalent aliquots of effluents from eye pair 1 (injected once at t  0)
analyzed by Western blot analysis with human anti-MMP1 and anti-
collagen type I antibodies. The MMP1 protein produced by the trans-
gene had high enzymatic activity.
FIGURE 9. Immunohistochemistry eval-
uation of MMP1 activity. Eye pairs
from nonglaucomatous donors were
perfused to stable baseline with
DMEM and followed by media ex-
change containing 0.1 M DEX in
both eyes (t  0). Eyes were injected
twice through an HPLC loop, and
perfusion continued in DMEM/DEX
media. One eye (OD; top) received
virus vehicle (t  0 and t  24 hours)
while the contralateral eye (OS; bot-
tom) received 6.2  109 vg/dose
AdhGRE.MMP1 at the same time
points. At t  6 days, anterior seg-
ments were fixed and embedded in
paraffin. Immunohistochemistry was
conducted by double labeling with
human anti-MMP1 and anti-collagen
type I, followed by fluorescence-
tagged Alexa Fluor 555 (for MMP1,
red) and Alexa Fluor 488 (for colla-
gen type I, green). Tissues were counterstained with DAPI (blue). Shown is a single representative frame from eye pair 2 captured under Texas
Red, FITC, and DAPI filters. Collagen type I was degraded where MMP1 was higher, especially on the SC wall and juxtacanalicular region. Note
the apparent widening of the SC area because of the degradation of collagen type I (bottom middle).
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experiments showed a downregulation of MMP1 of 500-fold on
DEX-treated cells for 6 days and of 2.4- and 6.2-fold on cells
treated with the other two steroids for shorter time periods.
We also found that the lower transcription of MMP1 resulted in
decreased levels of secreted MMP1 protein, a finding that fits
nicely with the decreased turnover and increased ECM depo-
sition known to occur in the outflow pathway on corticoste-
roid treatment.10 All these findings support the concept that
downregulated MMP1 protein has detrimental consequences
for trabecular meshwork function. Thus, to overcome the
MMP1 deficiency that occurs during a steroid administration
episode, we designed and engineered a delivery vector with an
inducible cassette upstream of the cDNA encoding MMP1. The
cassette included a GRE element to respond to the steroid, a
basal promoter, and an upstream blocker to avoid the genera-
tion of other, nonspecific transcripts.
We found that when primary cells of the human trabecular
meshwork were transduced with this vector (AdhGRE.MMP1),
they increased their expression of MMP1 mRNA 757-fold in the
presence of DEX but not in its absence. This is an indication
that, in a clinical setting, the vector would be active only
during steroid treatment. Most important, the cycle of induc-
tion/noninduction was carried over more than once in the
same cells. That is, cells transduced with the vector overex-
pressed MMP1 under the first exposure to DEX, returned to
basal level when the steroid was removed, and overexpressed
the enzyme again when exposed to DEX for a second time.
This cycled induction/silencing of the vector activity would be
of great value if a patient required separate steroid administra-
tions. Because some gene therapy vectors have been shown to
remain intracellular (as episomes) and to have the ability to
express their transgene for as long as 5 years,50 having this
inducible vector would mean that a single dose would be
sufficient and that further doses would not have to be reap-
plied when the next steroid treatment is required. During the
vector expression term, its transgene DNA would be present in
the eye but latent during periods when steroids are not admin-
istered.
Extensive characterization of the MMP1 protein produced
by this vector in human primary HTM cells and intact tissue
showed that the recombinant enzyme seems to have the same
characteristics as endogenous MMP1. In the primary HTM
cells, the protein is secreted as a proenzyme that is cleaved and
activated by APMA, a thiol-blocking reagent known to activate
latent procollagenases, which are enzyme-inhibitor complex-
es.39 After incubation with APMA and after using an anti-human
MMP1 antibody that detects pro-MMP1 and MMP1, we ob-
served the shift from the 51-kDa pro-MMP1 to the lower 41-kDa
active form of the human enzyme. Interestingly, the intracel-
lular MMP1 associated with cultured cell extracts contained
both forms of the enzyme, pro-MMP1 and MMP1. Regarding
the determination of the recombinant enzyme functional activ-
ity, our results showed that the liberated active secreted MMP1
retained its full ability to degrade collagen type I. This activity
was measured with a classic assay using exogenous native rat
collagen and with a state-of-the-art FRET technology assay us-
ing a fluorescence-labeled MMP peptide substrate. We further
showed the specificity of our results by comparing the expres-
sion behavior of the wild-type MMP1 adenovirus with that of a
parallel control carrying an identical inducible cassette but
with a mutant MMP1 cDNA containing a point mutation in the
cDNA region encoding the catalytic site of the MMP1, which
theoretically would produce an inactive enzyme. As hypothe-
sized, we found that the levels of mutant MMP1 mRNA and
protein were similar to those produced by the wild-type vec-
tor. However, the recombinant mutant protein was unable to
degrade collagen in both assays. Together these findings dem-
onstrate that the enzyme produced by the wild-type recombi-
nant vector has the specific ability to degrade components of
the trabecular meshwork ECM. Although the main role attrib-
uted to MMP1 is that of degradation of the ECM, this enzyme
could perform yet unidentified intracellular functions in the
human trabecular meshwork. The observation that some of the
recombinant enzyme appears associated with the nuclei is
intriguing and raises the possibility that MMP1 may play a role
in other cell functions as it has been shown in other cell
types.47
The MMP1 encoded by the AdhGRE.MMP1 vector was also
induced by steroids in a model of perfused human anterior
segments from postmortem donors. In these organ cultures,
the trabecular meshwork maintains its natural architecture,
and the perfused media flows in a manner that mimics the flow
of aqueous humor through the tissue. Organ cultures also have
the advantage of their serum-free culture conditions (important
for the study of secreted proteins) and the characteristic of
maintaining expression of many genes that get downregulated
once the cells are placed in standard tissue cultures. Most
important, experiments with paired eyes allow the comparison
of vehicle- and vector-injected trabecular meshworks from
identical genetic backgrounds. Our results with organ cultures
confirmed all findings first observed on the HTM cultured cells.
The steroid-regulated increase of recombinant MMP1 was ob-
served at the level of transcription in the dissected tissue and
at the level of enzyme secretion in the effluents, showing a
further increase with perfusion time. Interestingly, at pre-DEX
perfusion, the trabecular meshwork secreted only the pro-
MMP1 form of the protein, whereas after perfusion with DEX
both vector and vehicle-injected eyes secreted the latent and
the active forms. At this time, we do not know why DEX
perfusion resulted in the secretion of the active form, which
was not observed in the cultured cells. The collagen activity of
the effluents measured by FRET was also found to be greatly
increased in the eye injected with the gene therapy vector.
Double-labeling immunohistochemistry showed that the in-
tensely stained regions of the delivered MMP1 overlapped with
the weak staining of collagen type I. To a lesser extent, West-
ern blot analysis revealed overall lower levels of collagen type
I in the eyes with higher MMP1 levels. Last, although the
number of eyes used in this study was not sufficient to assess
a significant change in outflow facility, we observed an increas-
ing trend in the eyes overexpressing MMP1. We interpreted
this result as a prelude of the possibility of lowering IOP in
vivo, which we subsequently demonstrated to occur in a large
animal model of steroid-induced hypertension (see Ref. 36).
Our study, though in a less advanced stage, could be com-
pared with those studies that use inducible gene therapy vec-
tors to treat disease rather than to replace genes and correct
genetic defects. Several inducible vectors are being engineered
for cancer treatment, some in advanced clinical trials. For
example, the TNFerade is an adenovirus vector in which radio-
and chemo-inducible elements from the early growth response
gene (Egr-1) promoter have been inserted upstream of a cDNA
encoding human tumor necrosis factor  (TNF).51 Local in-
jection of the vector into the tumor, followed by treatment
with radiation or chemotherapy, triggers TNF secretion and
enhances antitumor activity (ongoing phase III clinical trial). In
the same vein, vectors combining the heat shock protein pro-
moter with a catalytic subunit of diphtheria toxin are inducing
cell growth arrest on transfected cells after application of
heat.52 Gene therapy for the treatment of acquired diseases
continues to advance. Today, more than 60% of ongoing gene
therapy trials are designed to treat cancer53 with encouraging
results.54 Limitations and challenges relate primarily to the
immune responses to vectors and to the high cost of the
technology. However, some of the challenges of gene therapy
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are no different from those involving translational research of
other complex medical technologies.
The engineered vector used here was specifically designed
to be delivered into the anterior chamber to treat steroid-
induced glaucoma. Although this route of administration favors
gene delivery to the trabecular meshwork,21 the vector does
not yet contain trabecular meshwork target sequences. Once
we show that this vector is properly regulated by steroids and
is able to secrete an ECM deposition enzyme, additional im-
provements will follow. Experiments to switch the basal ge-
neric promoter by a trabecular meshwork-specific promoter
are under way. With the same adenovirus-type vector, we have
already determined that the 700/44-bp promoter region of
the B-crystallin gene targets the expression of a reporter gene
to the trabecular meshwork in organ cultures, living rats, and
monkeys (Spiga MG et al. IOVS 2008;48:E-Abstract 1612). This
B-crystallin promoter has been selected as a good candidate.
Finally, our laboratory has previously shown that adenovi-
rus vectors deliver transgenes to the trabecular meshwork of
living animals with high efficiency and that they do not inter-
fere with outflow facility of the aqueous humor.20,21 For these
reasons, combined with our longstanding adenoviral expertise,
we first selected an adenovirus for the testing of our new
strategy. However, adenovirus vectors might not be the ideal
final gene therapy vector to translate this strategy to the oph-
thalmology clinic for humans. Although highly efficient in
transduction, they have a relatively short-term transgene ex-
pression and can induce an inflammatory response under cer-
tain concentration conditions.21 Fortunately, we have recently
shown that a second-generation, self-complementary adenoas-
sociated virus (scAAV) was able to override the lack of trabec-
ular meshwork transduction of their AAV parent vectors. This
scAAV vector transduced the trabecular meshwork of living
monkeys for more than 2 years.25 Most significantly, the safety
of AAV vectors in the eye has been recently corroborated by
their success in clinical trials that restored sight in patients
with Leber amaurosis.55
In summary, our study provides the first gene therapy strat-
egy for the treatment of steroid-induced glaucoma. Our vector
design and engineering showed that a key ECM remodeling
enzyme, MMP1, can be induced and silenced by the presence
or absence of the steroid. The enzyme produced by the vector
under steroid conditions is similar, if not identical, to the
endogenous enzyme and retains the activity to degrade the
collagen type I MMP1 substrate. Overproduction of the en-
zyme counteracts its downregulation by corticosteroids. Our
findings are further strengthened by the ability of this gene
transfer vector to reduce elevated IOP in a model of steroid
ocular hypertension in sheep (see Ref. 36). Continuing devel-
opment of this vector would provide the opportunity to trans-
late our findings to the clinical setting and has the potential to
lead to the development of a treatment for steroid-induced
hypertension.
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